arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

HALOZYME THERAPEUTICS, INC.

HALO
$122.17 ▼ -8.20 (-6.29%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Neutral
auto_awesome

Analytical Summary

HALOZYME THERAPEUTICS, INC. demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Debt to Equity which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $14.6B
Dividend Yield —
Revenue Growth 37.6% ↗
Op. Margin 33.6% ↘
ROIC 14.5% ↘
FCF / Share $5.38 ↗
Trailing P/E 46.3x
Price / Book 294.8x
FCF Yield 4.4%
Debt / Equity 43.89
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.40B
↑ +37.6% —
Net Income Profit after all expenses
$316.89M
↓ -28.6% —
Operating Margin Operating profit as % of sales
33.6%
↓ -38.2% 89th
FCF / Share Free cash flow per share
$5.38
↑ +45.6% —
Long-Term Debt Long-term obligations
$2.14B
↑ +42.3% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↓
90
Financial Health ↑
46
Cash Quality ↑
86

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters